Catalyst Event
Hanmi Pharm Co Ltd (128940) · Earnings Release
From KRX Bio Technology Transfer Index (KBIOTT)
4/30/2026, 12:00:00 AM
Announced Q1 2026 results: Revenue KRW 392.9B (+0.5% YoY), Operating Profit KRW 53.6B (-9.1% YoY), Net Profit KRW 51.1B (+14.4% YoY). The operating profit decline was attributed to a one-off base effect from prior year's clinical trial material supply.
Korean Translation
2026년 1분기 실적 발표: 매출 3,929억원(전년 동기 대비 +0.5%), 영업이익 536억원(전년 동기 대비 -9.1%), 순이익 511억원(전년 동기 대비 +14.4%) 기록. 영업이익 감소는 전년 동기 파트너사 임상 시료 공급에 따른 일회성 기저효과 영향임.
Related Recent Events
AprilBio Co Ltd (397030) · Other
Final data from the Phase 1b clinical trial of APB-A1 for thyroid eye disease (TED) is scheduled to be presented at the ENDO conference on June 13, 2026. High importance is estimated due to the typical >10% price impact of clinical data, scheduled.
6/13/2026, 12:00:00 AM
LigaChem Biosciences Inc (141080) · Earnings Release
The company's quarterly earnings report is scheduled for May 18, 2026; a 5-10% price impact is estimated based on historical volatility, scheduled.
5/18/2026, 12:00:00 AM
Yuhan Corp (000100) · Earnings Release
Yuhan Corp. announced Q1 2026 earnings. Consolidated revenue was KRW 526.8B (+7.2% YoY) and operating profit was KRW 8.8B (+37.3% YoY). Operating profit missed market expectations due to the delayed recognition of a milestone payment for Lazertinib. Due to the earnings miss, a ~5% price impact is expected.
4/30/2026, 12:00:00 AM
Daewoong Pharmaceutical Co Ltd (069620) · Other
Announced a strategic investment in US biotech 'General Proximity' to secure next-generation 'Induced Proximity' drug development technology, on April 30, 2026.
4/30/2026, 12:00:00 AM
Chong Kun Dang Pharm Co (185750) · Earnings Release
Announced Q1 2026 earnings with revenue of KRW 447.7 billion (+12.2% YoY) and operating profit of KRW 17.6 billion (+36.9% YoY), beating market expectations.
4/29/2026, 12:00:00 AM
SK Biopharmaceuticals Co Ltd (326030) · Other
An executive vice president is scheduled to announce a long-term revenue target for Cenobamate (Xcopri), aiming for $1 billion in U.S. sales by 2029 at the Bio Korea 2026 event on April 29, 2026; high importance is estimated as the $1B target is a critical valuation milestone for blockbuster status, scheduled.
4/29/2026, 12:00:00 AM